Dr. Mike Burgess joined SpringWorks Therapeutics in 2021. He has more than 20 years of experience building and leading oncology R&D teams in pharmaceutical and biotechnology companies. Previously, Mike was President of R&D at Turnstone Biologics, where he led the build out of a leading cancer immunotherapy R&D organization. Before Turnstone, Mike led the strategy and execution of translational medicine, early-stage clinical trials and clinical pharmacology across all therapeutics areas, including oncology, at Bristol-Myers Squibb. Before Bristol-Myers Sqibb, he held several different senior leadership positions at Hoffmann La-Roche, including Acting Global Head of Roche Pharma Research and Early Development (pRED) and Senior Vice President and Global Head of Oncology Research and Early Development. Prior to Roche, Mike was with Eli Lilly and Company, where he worked on early-stage oncology trials. Mike received his medical degree (M.B.Ch.B.) and Ph.D. in molecular biology from the University of Bristol, UK and spent 10 years as a practicing physician in pediatrics and pediatric oncology.